FTC monitoring how drug companies react to patent cliff, official says

Core Viewpoint - The U.S. Federal Trade Commission (FTC) is actively monitoring anticompetitive practices in the pharmaceutical industry, particularly as several blockbuster drugs approach the end of their patent exclusivity, aiming to protect consumers from unfair pricing [1][3]. Group 1: FTC's Focus on Healthcare - The FTC has a "laser focus" on healthcare, particularly regarding the market changes due to patent expirations, ensuring that generic drugs can enter the market as intended under patent laws [2]. - The agency has blocked multiple deals in the healthcare sector to maintain competition, including a recent $356 million medical equipment merger that was abandoned due to FTC intervention [3]. Group 2: Impact of Patent Expirations - Many top-selling U.S. drugs, such as Merck's Keytruda, Bristol Myers Squibb and Pfizer's Eliquis, and J&J's Darzalex, are set to lose patent exclusivity by the end of the decade, which could significantly impact market dynamics [3]. Group 3: Innovation and Mergers - The FTC is concerned about how pharmaceutical mergers may affect innovation incentives, even for drugs still in the pipeline, emphasizing the importance of continued research and development [6]. - The agency's scrutiny extends to potential mergers that could reduce competition and slow innovation, as seen in the case of Alcon's abandoned bid to acquire Lensar [5].